logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
Showing 1 - 20 of 59 Items
Showing 1 - 20 of 59 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Protocol

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M,  et al.
2023-11-30 • Trials
2023-11-30 • Trials
BACKGROUND
Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...
Journal Article
|
Research

Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications

Rich ML, Khan UT, Zeng C, LaHood AN, Franke MF,  et al.
2023-06-01 • International Journal of Tuberculosis and Lung Disease
2023-06-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
Evidence of the effectiveness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB) is limited.

OB...
Journal Article
|
Research

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB

Zeng C, Mitnick CD, Hewison CCH, Bastard M, Khan PY,  et al.
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...
Journal Article
|
Research

Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid and other second-line drugs

Huerga H, Khan UT, Bastard M, Mitnick CD, Lachenal N,  et al.
2022-10-15 • Clinical Infectious Diseases
2022-10-15 • Clinical Infectious Diseases
BACKGROUND
Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-ben...
Journal Article
|
Research

Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort

Hewison CCH, Khan UT, Bastard M, Lachenal N, Coutisson S,  et al.
2022-09-15 • Clinical Infectious Diseases
2022-09-15 • Clinical Infectious Diseases
RATIONALE
Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an obstacle to treatment completion.

OBJECTIVES
Evaluate safety of longer MDR/RR-TB...
Journal Article
|
Commentary

Reply from the Authors of Eligibility for the Shorter MDR-TB Regimen: Ambiguities in the WHO Recommendations

Varaine FFV, Guglielmetti L, Mitnick CD
2017-07-17 • American Journal of Respiratory and Critical Care Medicine
2017-07-17 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|
Research

Outcomes from the first multidrug-resistant tuberculosis programme in Kenya

Huerga H, Bastard M, Kamene M, Wanjala S, Arnold A,  et al.
2017-03-01 • International Journal of Tuberculosis and Lung Disease
2017-03-01 • International Journal of Tuberculosis and Lung Disease
SETTING
In March 2006, the first multidrug-resistant tuberculosis (MDR-TB) treatment programme was implemented in Kenya.

OBJECTIVE
To describe patients' treatment outcom...
Journal Article
|
Letter

Revised definitions of multidrug-resistant tuberculosis treatment outcomes: closer to the reality?

Bastard M, Bonnet MMB, du Cros PAK, Khamraev AK, Hayrapetyan A,  et al.
2015-02-01 • American Journal of Respiratory and Critical Care Medicine
2015-02-01 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|
Research

Adherence to self-administered tuberculosis treatment in a high HIV-prevalence setting: a cross-sectional survey in Homa Bay, Kenya

Nackers F, Huerga H, Espie E, Aloo AO, Bastard M,  et al.
2012-03-12 • PLOS One
2012-03-12 • PLOS One
Good adherence to treatment is crucial to control tuberculosis (TB). Efficiency and feasibility of directly observed therapy (DOT) under routine program conditions have been questioned. ...
Journal Article
|
Research

Thin layer agar compared to BACTEC MGIT 960 for early detection of Mycobacterium tuberculosis

Martin AIC, Fissette K, Varaine FFV, Portaels F, Palomino JC
2009-05-07 • Journal of Microbiological Methods
2009-05-07 • Journal of Microbiological Methods
We compared the sensitivity and time to detection of growth of Mycobacterium tuberculosis in the thin layer agar (TLA) compared to BACTEC MGIT960. The average time for growth of M. tuber...
Journal Article
|
Research

Cetyl-pyridinium chloride is useful for isolation of Mycobacterium tuberculosis from sputa subjected to long-term storage

Pardini M, Varaine FFV, Iona E, Arzumanian E, Checchi F,  et al.
2005-01-01 • Journal of Clinical Microbiology
2005-01-01 • Journal of Clinical Microbiology
Recovery of Mycobacterium tuberculosis from sputa treated with cetyl-pyridinium chloride (CPC) and stored for 20 +/- 9 days was significantly higher than that from sputa that were untrea...
Journal Article
|
Research

Evaluation of combined LED-fluorescence microscopy and bleach sedimentation for diagnosis of tuberculosis at peripheral health service level

Bonnet MMB, Gagnidze L, Guerin PJ, Bonte L, Ramsay AR,  et al.
2011-05-31 • PLOS One
2011-05-31 • PLOS One
Sputum microscopy is the only diagnostic for tuberculosis (TB) available at peripheral levels of health service in resource-poor countries. Its sensitivity is reduced in high HIV-prevale...
Journal Article
|
Research

Does One Size Fit All? Drug Resistance and Standard Treatments: Results of Six Tuberculosis Programmes in Former Soviet Countries

Bonnet MMB, Sizaire V, Kebede YYK, Janin A, Doshetov D,  et al.
2005-10-01 • International Journal of Tuberculosis and Lung Disease
2005-10-01 • International Journal of Tuberculosis and Lung Disease
SETTING: After the collapse of the Soviet Union, countries in the region faced a dramatic increase in tuberculosis cases and the emergence of drug resistance. OBJECTIVE: To discuss the r...
Journal Article
|
Letter

Eligibility for the shorter multidrug-resistant tuberculosis regimen: ambiguities in the World Health Organization recommendations

Varaine FFV, Guglielmetti L, Huerga H, Bonnet MMB, Kiria N,  et al.
2016-10-15 • American Journal of Respiratory and Critical Care Medicine
2016-10-15 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|
Research

Reducing the Number of Sputum Samples Examined and Thresholds for Positivity: An Opportunity to Optimise Smear Microscopy

Bonnet MMB, Ramsay AR, Gagnidze L, Githui W, Guerin PJ,  et al.
2007-09-01 • International Journal of Tuberculosis and Lung Disease
2007-09-01 • International Journal of Tuberculosis and Lung Disease
SETTING: Urban health clinic, Nairobi. OBJECTIVE: To evaluate the impact on tuberculosis (TB) case detection and laboratory workload of reducing the number of sputum smears examined and ...
Journal Article
|
Research

Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a quantitative and qualitative study

Sanchez-Padilla E, Marquer C, Kalon S, Qayyum S, Hayrapetyan A,  et al.
2014-02-01 • International Journal of Tuberculosis and Lung Disease
2014-02-01 • International Journal of Tuberculosis and Lung Disease
SETTING
Armenia, a country with a high prevalence of drug-resistant tuberculosis (DR-TB).

OBJECTIVE
To identify factors related to default from DR-TB treatment in Yereva...
Journal Article
|
Research

Implementing the Xpert MTB/RIF diagnostic test for tuberculosis and rifampicin resistance: outcomes and lessons learned in 18 countries

Ardizzoni E, Fajardo E, Saranchuk P, Casenghi M, Page AL,  et al.
2015-12-15 • PLOS One
2015-12-15 • PLOS One
BACKGROUND
The Xpert® MTB/RIF (Xpert) is an automated molecular test for simultaneous detection of tuberculosis (TB) and rifampicin resistance, recommended by the World Health Organi...
Journal Article
|
Commentary

Introducing new and repurposed TB drugs: the endTB experience

Seung KJ, Khan UT, Varaine FFV, Ahmed SM, Bastard M,  et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major imp...
Journal Article
|
Research

Thin-layer agar for detection of resistance to rifampicin, ofloxacin and kanamycin in Mycobacterium tuberculosis isolates

Martin AIC, Paasch F, Von Groll A, Fissette K, Almeida P,  et al.
2009-10-01 • International Journal of Tuberculosis and Lung Disease
2009-10-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
In low-income countries there is a great need for economical methods for testing the susceptibility of Mycobacterium tuberculosis to antibiotics.

OBJECTIVE
T...
Journal Article
|
Research

Effects of Treatment Interruption Patterns on Treatment Success Among Patients With Multidrug-Resistant Tuberculosis in Armenia and Abkhazia

Bastard M, Sanchez-Padilla E, Hewison CCH, Hayrapetyan A, Khurkhumal S,  et al.
2014-10-13 • Journal of Infectious Diseases
2014-10-13 • Journal of Infectious Diseases
The success of the current treatment regimen for multidrug-resistant tuberculosis (MDR-TB) is poor partly due to a high defaulter rate. Many studies explored predictors of poor outcomes,...